$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

$halo Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-K Financial Statement

#000115903617000014 Filed on February 28, 2017

Income Statement

Concept	2016 Q4	2016 Q2	2016 Q1
Revenue	$39.00M	$33.34M	$42.50M
YoY Change	0.0%	0.0%	0.0%
Cost Of Revenue	$8.000M	$8.308M	$7.762M
YoY Change	-4.76%	2.01%	19.53%
Gross Profit	$5.420M	$5.391M	$5.178M
YoY Change	0.0%	0.0%	0.0%
Gross Profit Margin	13.9%	16.17%	12.18%
Selling, General & Admin	$12.20M	$11.22M	$10.81M
YoY Change	15.09%	14.34%	14.97%
% of Gross Profit	225.09%	208.14%	208.69%
Research & Development	$41.30M	$35.53M	$40.10M
YoY Change	49.1%	67.63%	140.35%
% of Gross Profit	761.99%	659.06%	774.43%
Depreciation & Amortization	$600.0K	$600.0K	$489.0K
YoY Change	20.0%	50.0%	16.15%
% of Gross Profit	11.07%	11.13%	9.44%
Operating Expenses	$61.58M	$55.06M	$58.67M
YoY Change	60.36%	77.56%	124.93%
Operating Profit	-$56.16M	-$21.72M	-$16.17M
YoY Change	70.28%	-613.42%	16.23%
Interest Expense	-$5.200M	$5.249M	$3.876M
YoY Change	372.73%	304.08%	198.38%
% of Operating Profit
Other Income/Expense, Net		$397.0K	$229.0K
YoY Change		356.32%	124.51%
Pretax Income	-$27.80M	-$26.58M	-$19.82M
YoY Change	-746.51%	-980.26%	31.23%
Income Tax	-$400.0K	$300.0K	$0.00
% Of Pretax Income
Net Earnings	-$27.39M	-$26.88M	-$19.82M
YoY Change	0.0%	0.0%	0.0%
Net Earnings / Revenue	-70.22%	-80.62%	-46.63%
Basic Earnings Per Share	$0.03	-$0.21	-$0.16
Diluted Earnings Per Share	$0.03	$0.02	-$0.12
COMMON SHARES
Basic Shares Outstanding	127.2M shares	128.0M shares	127.6M shares
Diluted Shares Outstanding	129.2M shares	134.5M shares	125.3M shares

Balance Sheet

Concept	2016 Q4	2016 Q2	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$205.0M	$230.0M	$238.6M
YoY Change	89.29%	63.47%	85.68%
Cash & Equivalents	$66.76M	$61.23M	$69.09M
Short-Term Investments	$138.2M	$168.8M	$169.5M
Other Short-Term Assets	$21.20M	$20.40M	$22.50M
YoY Change	-1.4%	98.06%	134.38%
Inventory	$14.62M	$10.76M	$10.35M
Prepaid Expenses	$9.663M	$16.74M
Receivables	$15.68M	$23.23M	$25.54M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$256.5M	$284.3M	$297.0M
YoY Change	49.34%	68.81%	93.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.264M	$4.682M	$4.440M
YoY Change	8.14%	80.49%	62.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$700.0K	$7.100M	$7.600M
YoY Change	-88.52%	136.67%	145.16%
Total Long-Term Assets	$4.983M	$11.78M	$12.06M
YoY Change	-50.25%	110.22%	108.09%
TOTAL ASSETS
Total Short-Term Assets	$256.5M	$284.3M	$297.0M
Total Long-Term Assets	$4.983M	$11.78M	$12.06M
Total Assets	$261.5M	$296.1M	$309.1M
YoY Change	43.86%	70.14%	94.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.578M	$3.650M	$6.211M
YoY Change	-20.47%	-11.79%	88.27%
Accrued Expenses	$28.82M	$23.85M	$21.79M
YoY Change	7.57%	60.93%	70.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$17.39M	$3.288M	$27.42M
YoY Change	-20.44%	-65.95%	635.04%
Total Short-Term Liabilities	$54.59M	$38.89M	$64.22M
YoY Change	-12.6%	10.98%	145.04%
LONG-TERM LIABILITIES
Long-Term Debt	$199.2M	$204.9M	$168.6M
YoY Change	612.27%	410.97%	266.52%
Other Long-Term Liabilities	$358.0K	$600.0K	$3.906M
YoY Change	-91.94%	-82.5%	24.91%
Total Long-Term Liabilities	$199.6M	$600.0K	$3.906M
YoY Change	515.74%	-82.5%	24.91%
TOTAL LIABILITIES
Total Short-Term Liabilities	$54.59M	$38.89M	$64.22M
Total Long-Term Liabilities	$199.6M	$600.0K	$3.906M
Total Liabilities	$254.2M	$39.49M	$68.13M
YoY Change	167.91%	2.64%	132.24%
SHAREHOLDERS EQUITY
Retained Earnings	-$585.3M	-$529.0M	-$502.1M
YoY Change	21.27%	14.38%	7.86%
Common Stock	$552.9M	$538.7M	$531.5M
YoY Change	5.16%	5.06%	5.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$32.48M	$9.920M	$29.47M
YoY Change
Total Liabilities & Shareholders Equity	$261.5M	$296.1M	$309.1M
YoY Change	43.86%	70.14%	94.25%

Cashflow Statement

Concept	2016 Q4	2016 Q2	2016 Q1
OPERATING ACTIVITIES
Net Income	-$27.39M	-$26.88M	-$19.82M
YoY Change	0.0%	0.0%	0.0%
Depreciation, Depletion And Amortization	$600.0K	$600.0K	$489.0K
YoY Change	20.0%	50.0%	16.15%
Cash From Operating Activities	-$15.80M	-$12.90M	-$13.00M
YoY Change	3.95%	-244.94%	-6.06%
INVESTING ACTIVITIES
Capital Expenditures	-$400.0K	-$1.200M	$1.099M
YoY Change	-76.47%	300.0%	745.38%
Acquisitions
YoY Change
Other Investing Activities	$21.50M	$700.0K	-$104.5M
YoY Change	-262.88%	-93.64%	914.56%
Cash From Investing Activities	$21.00M	-$500.0K	-$105.6M
YoY Change	-242.86%	-104.63%	913.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	300.0K	5.500M	144.4M
YoY Change	-82.35%	48.65%	1917.61%
NET CHANGE
Cash From Operating Activities	-15.80M	-12.90M	-13.00M
Cash From Investing Activities	21.00M	-500.0K	-105.6M
Cash From Financing Activities	300.0K	5.500M	144.4M
Net Change In Cash	5.500M	-7.900M	25.80M
YoY Change	-119.5%	-133.76%	-250.86%
FREE CASH FLOW
Cash From Operating Activities	-$15.80M	-$12.90M	-$13.00M
Capital Expenditures	-$400.0K	-$1.200M	$1.099M
Free Cash Flow	-$15.40M	-$11.70M	-$14.10M
YoY Change	14.07%	-227.17%	0.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016	dei	Amendment Flag AmendmentFlag	false
CY2016	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2016	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016	dei	Document Period End Date DocumentPeriodEndDate	2016-12-31
CY2016	dei	Document Type DocumentType	10-K
CY2016	dei	Entity Central Index Key EntityCentralIndexKey	0001159036
CY2017Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	129764415	shares
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2016Q2	dei	Entity Public Float EntityPublicFloat	1100000000	USD
CY2016	dei	Entity Registrant Name EntityRegistrantName	HALOZYME THERAPEUTICS INC
CY2014	halo	Manufacturingcostspreviouslyrecordedasresearchanddevelopment Manufacturingcostspreviouslyrecordedasresearchanddevelopment	1000000	USD
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2015Q4	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	25939000	USD
CY2016Q4	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	6151000	USD
CY2015Q4	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	2442000	USD
CY2015	halo	Manufacturingcostspreviouslyrecordedasresearchanddevelopment Manufacturingcostspreviouslyrecordedasresearchanddevelopment	0	USD
CY2016	halo	Contingentmilestonepayment Contingentmilestonepayment	8000000	USD
CY2016Q4	halo	Long Term Debt Including Interest Gross LongTermDebtIncludingInterestGross	266360000	USD
CY2016Q4	halo	Long Term Debt Interest Gross LongTermDebtInterestGross	45208000	USD
CY2016Q4	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	2234000	USD
CY2015Q4	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	4996000	USD
CY2016Q4	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	7854000	USD
CY2015Q4	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	8617000	USD
CY2016Q4	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	9522000	USD
CY2015Q4	halo	Accrued Outsourced Researchand Development Expenses Long Term AccruedOutsourcedResearchandDevelopmentExpensesLongTerm	784000	USD
CY2016Q4	halo	Accrued Outsourced Researchand Development Expenses Long Term AccruedOutsourcedResearchandDevelopmentExpensesLongTerm	17000	USD
CY2015Q4	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	6205000	USD
CY2016Q4	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	3225000	USD
CY2016Q4	halo	Additional Maximum Proceeds Receivablefrom Collaboratorof Licenseand Collaborative Agreement Upon Achievementof Clinical Development Milestones AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones	62500000	USD
CY2016Q4	halo	Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets	12000000	USD
CY2015Q4	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	967000	USD
CY2016Q4	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	559000	USD
CY2016	halo	Manufacturingcostspreviouslyrecordedasresearchanddevelopment Manufacturingcostspreviouslyrecordedasresearchanddevelopment	0	USD
CY2016	halo	Period For Termination PeriodForTermination	P90D
CY2015Q4	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	9225000	USD
CY2016Q4	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	8613000	USD
CY2016	halo	Restrictedstockawardholderexerciseprice Restrictedstockawardholderexerciseprice	0
CY2016	halo	Revenueamortizationoflicensepayments Revenueamortizationoflicensepayments	4100000	USD
CY2016	halo	Share Based Compensation Arrangement By Share Based Payment Award Options Exercise Price Percent Of Share Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice	1
CY2016	halo	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Initial Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm	P10Y
CY2014Q1	halo	Stock Issued During Period Shares New Issues To Underwriter StockIssuedDuringPeriodSharesNewIssuesToUnderwriter	1153846	shares
CY2016Q4	halo	Unrecognized Tax Benefitsthat Would Impact Effective Tax Ratenovaluationallowance UnrecognizedTaxBenefitsthatWouldImpactEffectiveTaxRatenovaluationallowance	12600000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4499000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3578000	USD
CY2015Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	33377000	USD
CY2016Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	16239000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	32410000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15680000	USD
CY2014	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1457000	USD
CY2015	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-879000	USD
CY2016	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-552000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	26792000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28821000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	27576000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	28838000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10318000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11919000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-99000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	525628000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	552737000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15274000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20838000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25585000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15274000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20838000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25585000	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2014	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2025000	USD
CY2015	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1243000	USD
CY2016	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2896000	USD
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8405903	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9780593	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13761123	shares
CY2015Q4	us-gaap	Assets Assets	181789000	USD
CY2016Q4	us-gaap	Assets Assets	261515000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	171772000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	256532000	USD
CY2015Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	25000	USD
CY2015Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	99000	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	31000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	65047000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	138217000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	65146000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	138223000	USD
CY2015Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	65047000	USD
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	138217000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	132200000	USD
CY2014	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2015	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2016	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2016Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	11
CY2014	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	156000	USD
CY2015	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	473000	USD
CY2016	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	75000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27357000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61389000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43292000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66764000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	34032000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-18097000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	23472000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9001562	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	128152000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	129502000	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	128152000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	129502000	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	128000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	130000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-68433000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32289000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-102930000	USD
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	22732000	USD
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	29245000	USD
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	33206000	USD
CY2014	us-gaap	Costs And Expenses CostsAndExpenses	138370000	USD
CY2015Q1	us-gaap	Costs And Expenses CostsAndExpenses	58668000	USD
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	55059000	USD
CY2015Q3	us-gaap	Costs And Expenses CostsAndExpenses	54596000	USD
CY2015Q4	us-gaap	Costs And Expenses CostsAndExpenses	61578000	USD
CY2015	us-gaap	Costs And Expenses CostsAndExpenses	162509000	USD
CY2016Q1	us-gaap	Costs And Expenses CostsAndExpenses	32577000	USD
CY2016Q2	us-gaap	Costs And Expenses CostsAndExpenses	39153000	USD
CY2016Q3	us-gaap	Costs And Expenses CostsAndExpenses	44017000	USD
CY2016Q4	us-gaap	Costs And Expenses CostsAndExpenses	46762000	USD
CY2016	us-gaap	Costs And Expenses CostsAndExpenses	229901000	USD
CY2016Q4	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0	USD
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1145000	USD
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	17000	USD
CY2016Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	221152000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	4531000	USD
CY2016Q4	us-gaap	Deferred Revenue DeferredRevenue	43900000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	9304000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	4793000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	43919000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	39825000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	16344000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	15354000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	182887000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	203710000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	380000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	340000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	104505000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	103296000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	906000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2515000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	54846000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	73701000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6286000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8844000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	182507000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	203370000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	380000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	340000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	380000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	340000	USD
CY2014	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	700000	USD
CY2015	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	700000	USD
CY2016	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1000000	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1762000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1677000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2410000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2015Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.81
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8636000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11539000	USD
CY2014	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	7800000	USD
CY2015	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	14400000	USD
CY2016	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	2800000	USD
CY2016	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2015Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2016Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2014	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-233000	USD
CY2015	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-8000	USD
CY2016	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-8000	USD
CY2015Q1	us-gaap	Gross Profit GrossProfit	5178000	USD
CY2015Q2	us-gaap	Gross Profit GrossProfit	5391000	USD
CY2015Q3	us-gaap	Gross Profit GrossProfit	4197000	USD
CY2015Q4	us-gaap	Gross Profit GrossProfit	5420000	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	3366000	USD
CY2016Q2	us-gaap	Gross Profit GrossProfit	4198000	USD
CY2016Q3	us-gaap	Gross Profit GrossProfit	4121000	USD
CY2016Q4	us-gaap	Gross Profit GrossProfit	5152000	USD
CY2016	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2016	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-30885000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	11724000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	6384000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-68375000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32231000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-101861000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-37490000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-43955000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-108245000	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1162000	USD
CY2014	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	0	USD
CY2015	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	0	USD
CY2016	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	1162000	USD
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	16998000	USD
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4045000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	11252000	USD
CY2014	us-gaap	Income Tax Reconciliation Deductions IncomeTaxReconciliationDeductions	0	USD
CY2015	us-gaap	Income Tax Reconciliation Deductions IncomeTaxReconciliationDeductions	11161000	USD
CY2016	us-gaap	Income Tax Reconciliation Deductions IncomeTaxReconciliationDeductions	14956000	USD
CY2014	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	12747000	USD
CY2015	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	14945000	USD
CY2016	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	36803000	USD
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-23247000	USD
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-10959000	USD
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-34633000	USD
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	1069000	USD
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	6457000	USD
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	698000	USD
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-529000	USD
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-4990000	USD
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	3735000	USD
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1761000	USD
CY2015	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	5524000	USD
CY2016	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-653000	USD
CY2014	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	5277000	USD
CY2015	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3861000	USD
CY2016	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1084000	USD
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	1441000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-816000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	13866000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-244000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	52000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	23261000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-16730000	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4379000	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	7045000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5626000	USD
CY2014	us-gaap	Interest Expense InterestExpense	5581000	USD
CY2015	us-gaap	Interest Expense InterestExpense	5201000	USD
CY2016	us-gaap	Interest Expense InterestExpense	19977000	USD
CY2014	us-gaap	Interest Expense Debt InterestExpenseDebt	5600000	USD
CY2015	us-gaap	Interest Expense Debt InterestExpenseDebt	5200000	USD
CY2016	us-gaap	Interest Expense Debt InterestExpenseDebt	20000000	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	701000	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	236000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3083000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5134000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	265000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	15774000	USD
CY2014	us-gaap	Interest Paid InterestPaid	3460000	USD
CY2015	us-gaap	Interest Paid InterestPaid	3775000	USD
CY2016	us-gaap	Interest Paid InterestPaid	3886000	USD
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	331000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1012000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	9489000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	14623000	USD
CY2015Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	677000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	761000	USD
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	8481000	USD
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	12850000	USD
CY2014	us-gaap	Investment Income Net InvestmentIncomeNet	242000	USD
CY2015	us-gaap	Investment Income Net InvestmentIncomeNet	422000	USD
CY2016	us-gaap	Investment Income Net InvestmentIncomeNet	1326000	USD
CY2015Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	103642000	USD
CY2016Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	199133000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	181789000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	261515000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	62457000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	54585000	USD
CY2014	us-gaap	License And Services Revenue LicenseAndServicesRevenue	28086000	USD
CY2015	us-gaap	License And Services Revenue LicenseAndServicesRevenue	58000000	USD
CY2016	us-gaap	License And Services Revenue LicenseAndServicesRevenue	42315000	USD
CY2015Q4	us-gaap	Long Term Debt LongTermDebt	27971000	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	199228000	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	21862000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	17393000	USD
CY2016Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	216621000	USD
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	37338000	USD
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	4755000	USD
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	24103000	USD
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	105758000	USD
CY2016Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	94406000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	199228000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	114501000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13098000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	150621000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32951000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5888000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-76766000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47518000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37083000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50383000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-68375000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-19816000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-26875000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-28946000	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-27386000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-32231000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-15108000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	3019000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-24460000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	4318000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-103023000	USD
CY2016	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-63036000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-27452000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-83210000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	4031000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2622000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	36000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	426000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	425000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	522000	USD
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1900000	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1900000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2200000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4118000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4552000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	3200000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	1100000	USD
CY2015Q4	us-gaap	Other Assets OtherAssets	530000	USD
CY2016Q4	us-gaap	Other Assets OtherAssets	1530000	USD
CY2014	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-58000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-58000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	93000	USD
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-58000	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-58000	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	93000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4443000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	358000	USD
CY2014	us-gaap	Other Noncash Expense OtherNoncashExpense	92000	USD
CY2015	us-gaap	Other Noncash Expense OtherNoncashExpense	441000	USD
CY2016	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2014	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	108000	USD
CY2015	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	276000	USD
CY2016	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	370000	USD
CY2015Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1198000	USD
CY2016Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1661000	USD
CY2014	us-gaap	Other Restructuring Costs OtherRestructuringCosts	0	USD
CY2014	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2015	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2016	us-gaap	Paid In Kind Interest PaidInKindInterest	13184000	USD
CY2014	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	88884000	USD
CY2015	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	71482000	USD
CY2016	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	155412000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1368000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2360000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3137000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	27108000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	21467000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	21534000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	21248000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	5574000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	219000	USD
CY2015Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	16155000	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9663000	USD
CY2014	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	USD
CY2015	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	USD
CY2016	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	203006000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107700000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107713000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	6788000	USD
CY2015	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	13098000	USD
CY2016	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1865000	USD
CY2014	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	57301000	USD
CY2015	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	79730000	USD
CY2016	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	81783000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14261000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16183000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3943000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4264000	USD
CY2016	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P3Y
CY2014	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	5554000	USD
CY2015	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	5789000	USD
CY2016	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	9304000	USD
CY2014	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	USD
CY2015	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	USD
CY2016	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	54250000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79696000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	93236000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	150842000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2014	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.13
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-482658000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-585342000	USD
CY2014	us-gaap	Revenues Revenues	75334000	USD
CY2015Q1	us-gaap	Revenues Revenues	42499000	USD
CY2015Q2	us-gaap	Revenues Revenues	33336000	USD
CY2015Q3	us-gaap	Revenues Revenues	31853000	USD
CY2015Q4	us-gaap	Revenues Revenues	39003000	USD
CY2015	us-gaap	Revenues Revenues	135057000	USD
CY2016Q1	us-gaap	Revenues Revenues	18666000	USD
CY2016Q2	us-gaap	Revenues Revenues	43384000	USD
CY2016Q3	us-gaap	Revenues Revenues	20780000	USD
CY2016Q4	us-gaap	Revenues Revenues	52227000	USD
CY2016	us-gaap	Revenues Revenues	146691000	USD
CY2014	us-gaap	Royalty Revenue RoyaltyRevenue	9425000	USD
CY2015	us-gaap	Royalty Revenue RoyaltyRevenue	30975000	USD
CY2016	us-gaap	Royalty Revenue RoyaltyRevenue	50984000	USD
CY2014Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	13.00
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	37823000	USD
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	46082000	USD
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	53392000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	25585000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	35942000	USD
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40028000	USD
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	45853000	USD
CY2014	us-gaap	Severance Costs1 SeveranceCosts1	1200000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	15274000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	20838000	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0204
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0192
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0190
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0173
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0134
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0100
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	8100000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	16200000	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1400000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1185960	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	407936	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	955054	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	9.39
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	10.64
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	12.42
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2271143	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3973604	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4466306	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.13
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.60
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.36
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	9400000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6700915	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6353892	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7993192	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11091196	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.11
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.18
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.03
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.70
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	4700000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	4230638	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	11.77
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	9400000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	11091196	shares
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.03
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.70
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.43
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.49
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.88
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	13.02
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	16.26
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y5M
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y2M
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y9M
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8846153	shares
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1432206	shares
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1926368	shares
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	413248	shares
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	107713000	USD
CY2014	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2015	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2016	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-83000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6788000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13098000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1948000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-19990000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	41352000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	42999000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-32481000	USD
CY2015Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	0	USD
CY2016Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	0	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4898000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12799000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12800000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2015	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2016	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	4898000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2015	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2016	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	4898000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	7184000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	5615000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	200000	USD
CY2013Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	610000	USD
CY2014Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	611000	USD
CY2015Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	967000	USD
CY2016Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	559000	USD
CY2014	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	4520000	USD
CY2015	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	4150000	USD
CY2016	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	4795000	USD
CY2014	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	4519000	USD
CY2015	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	3794000	USD
CY2016	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	5203000	USD
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	125299000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	134507000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	126921000	shares
CY2016Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	129248000	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	122690000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	127615000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	127958000	shares
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	128154000	shares
CY2015Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	128185000	shares
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	126704000	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	127964000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	125299000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	126144000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	126921000	shares
CY2016Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	127197000	shares
CY2016	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk, Sources of Supply and Significant Customers</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. We maintain our cash and cash equivalent balances with one major commercial bank and marketable securities with another financial institution. Deposits held with the financial institutions exceed the amount of insurance provided on such deposits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities to the extent recorded on the consolidated balance sheets. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also subject to credit risk from our accounts receivable related to our product sales and revenues under our license and collaborative agreements. We have license and collaborative agreements with pharmaceutical companies under which we receive payments for license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk formulation of rHuPH20. In addition, we sell </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> recombinant in the United States to a limited number of established wholesale distributors in the pharmaceutical industry. Credit is extended based on an evaluation of the customer’s financial condition, and collateral is not required. Management monitors our exposure to accounts receivable by periodically evaluating the collectibility of the accounts receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the customer and historical experience.</font></div></div>
CY2016	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Business</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. We are seeking to translate our unique knowledge of the tumor microenvironment to create therapies that have the potential to improve cancer patient survival. Our research primarily focuses on human enzymes that alter the extracellular matrix and tumor microenvironment. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for potential clinical benefit. We exploit our technology and expertise using a two pillar strategy that we believe enables us to manage risk and cost by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products that combine our technology with the collaborators’ proprietary compounds.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of our approved product and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> recombinant, and it works by temporarily breaking down hyaluronan (or “HA”), a naturally occurring complex carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We believe this temporary degradation creates an opportunistic window for the improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">™</sup></font><font style="font-family:inherit;font-size:10pt;"> Technology. We license the ENHANZE Technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Baxalta US Inc. and Baxalta GmbH (Baxalta Incorporated was acquired by Shire plc in June 2016) (“Baxalta”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), and Eli Lilly and Company (“Lilly”). We receive royalties from two of these collaborations, including royalties from sales of one product approved in both the United States and outside the United States from the Baxalta collaboration and from sales of two products approved for marketing outside the United States from the Roche collaboration. Future potential revenues from the sales and/or royalties of our approved products, product candidates, and ENHANZE collaborations will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary development pipeline consists primarily of pre-clinical and clinical stage product candidates in oncology. Our lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a molecular entity we are developing in combination with currently approved cancer therapies as a candidate for the systemic treatment of tumors that accumulate HA. We have demonstrated that when HA accumulates in a tumor, it can cause higher pressure in the tumor, reducing blood flow into the tumor and with that, reduced access of cancer therapies to the tumor. PEGPH20 has been demonstrated in animal models to work by temporarily degrading HA surrounding cancer cells resulting in reduced pressure and increased blood flow to the tumor thereby enabling increased amounts of anticancer treatments administered concomitantly gaining access to the tumor. Through our efforts and efforts of our partners and collaborators, we are currently in Phase 2 and Phase 3 clinical testing for PEGPH20 with ABRAXANE</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></font><font style="font-family:inherit;font-size:10pt;">(nab-paclitaxel) and gemcitabine in stage IV pancreatic ductal adenocarcinoma (“PDA”) (Studies 109-202 and 109-301), in Phase 1b clinical testing for</font><font style="font-family:inherit;font-size:11pt;"> </font><font style="font-family:inherit;font-size:10pt;">PEGPH20 with KEYTRUDA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></font><font style="font-family:inherit;font-size:10pt;">(pembrolizumab) in non-small cell lung cancer and gastric cancer (Study 107-101) and in Phase 1b/2 clinical testing for PEGPH20 with HALAVEN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> (eribulin) in patients treated with up to two lines of prior therapy for HER2-negative metastatic breast cancer.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd., Halozyme Royalty LLC and Halozyme Switzerland GmbH.</font></div></div>
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001159036-17-000014-index-headers.html	Edgar Link	pending
0001159036-17-000014-index.html	Edgar Link	pending
0001159036-17-000014.txt	Edgar Link	pending
0001159036-17-000014-xbrl.zip	Edgar Link	pending
ex10222011stockplan-rsuagr.htm	Edgar Link	pending
ex1033oxford_svb1stamendme.htm	Edgar Link	pending
ex211subsidiaries2016.htm	Edgar Link	pending
ex23110k2016.htm	Edgar Link	pending
ex31110k2016.htm	Edgar Link	pending
ex31210k2016.htm	Edgar Link	pending
ex3210k2016.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
halo-12312016x10k.htm	Edgar Link	pending
halo-20161231.xml	Edgar Link	completed
halo-20161231.xsd	Edgar Link	pending
halo-20161231_cal.xml	Edgar Link	unprocessable
halo-20161231_def.xml	Edgar Link	unprocessable
halo-20161231_lab.xml	Edgar Link	unprocessable
halo-20161231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
slide1a26.jpg	Edgar Link	pending
slide2a21.jpg	Edgar Link	pending
slide3a20.jpg	Edgar Link	pending
stockpricea03.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

2016 Q4 Form 10-K Financial Statement

#000115903617000014 Filed on February 28, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO HALOZYME THERAPEUTICS, INC. Stock $halo

2016 Q4 Form 10-K Financial Statement

#000115903617000014 Filed on February 28, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo